Administered IV as single bolus inj. May be given into an existing IV line. Adult For rocuronium & vecuronium 4 mg/kg if recovery has reached at least 1-2 post-tetanic counts (PTC) or 2 mg/kg if spontaneous recovery has occurred up to at least the reappearance of T2 following rocuronium- or vecuronium-induced blockade. For rocuronium only 16 mg/kg administered 3 min after a bolus dose of rocuronium Br 1.2 mg/kg.
Possibility of drug hypersensitivity reactions. Occurrence of light anesth, in rare instances marked bradycardia; use in ICU. Monitor resp function during recovery/coagulation parameters in patients w/ known coagulopathies or taking anticoagulants. Mandatory ventilatory support until adequate spontaneous respiration is restored & ability to maintain patent airway is assured. Prolonged neuromuscular blockade. If rocuronium re-administration is required, 24-hr waiting time is recommended. Displacement interactions w/ other drugs. Not recommended to use lower doses than recommended; may increase risk of neuromuscular blockade recurrence. Not to be used for reversal of block induced by nonsteroidal neuromuscular blockers (eg, succinylcholine or benzylisoquinolinium compd) or steroidal neuromuscular blockers other than rocuronium. Longer recovery time in CV disease or history of pulmonary complications. Hepatic & severe renal (CrCl <30 mL/min) impairment. Pregnancy & lactation. Female patients of reproductive potential must use additional non-hormonal contraceptive for the next 7 days following sugammadex administration. Childn.
Delayed recovery time w/ toremifene (received on the same day of the operation). Reduced effects & effectiveness of progestogen & OC steroids (either combined or progestogen only). Interference w/ serum progesterone assay.
Sign Out
